KRAS and neoplasm: Pathway analysis of RNA-seq gene expression data from ARPC and NEPC cell lines and dissociated tumor cells treated with romidepsin showed enrichment in EMT, KRAS signaling, and inflammatory signaling and de-enrichment in Myc targets, E2F targets, and G2–M checkpoint (Supplementary Fig. S12A), in line with our data with fimepinostat therapy (Fig. 3B, E).